Kisspeptin

What is Kisspeptin?

Kisspeptin is a neuropeptide originally discovered in 1996 as a tumor metastasis suppressor — hence its alternative name “metastin” — before its fundamental role as the master regulator of the hypothalamic-pituitary-gonadal (HPG) reproductive axis was identified. This seemingly contradictory functional duality reflects the breadth of its biological effects, which extend well beyond reproduction.

The KISS1 gene encodes a 145 amino acid precursor protein that, through proteolytic processing, gives rise to several bioactive peptides: kisspeptin-54 (KP-54), kisspeptin-14 (KP-14), kisspeptin-13 (KP-13), and kisspeptin-10 (KP-10). All share the C-terminal end and bind to the same receptor (GPR54), though with different potencies and pharmacokinetics. KP-10 is the shortest fragment with full activity on GPR54 and the most commonly used in research protocols due to its greater ease of synthesis and relative stability.

The discovery that mutations in KISS1 or GPR54 cause idiopathic hypogonadotropic hypogonadism (absence of puberty and reproductive function) in humans and mice was the critical piece confirming its role as the reproductive axis “switch.”

Mechanism of Action

Kisspeptin acts on GnRH (gonadotropin-releasing hormone)-producing neurons in the hypothalamus, specifically in the arcuate (ARC) and infundibular nuclei, where it activates the GPR54 receptor (also called KiSS1R). This activation triggers:

GnRH release: GnRH neurons increase the frequency and amplitude of their GnRH pulses into the hypothalamic-portal circulation.

Gonadotropic stimulation: GnRH acts on pituitary gonadotrophs to release LH (luteinizing hormone) and FSH (follicle-stimulating hormone).

Gonadal steroidogenesis: LH stimulates testosterone production in Leydig cells (males) and estrogen and progesterone production in the ovary (females). FSH promotes ovarian follicular maturation and spermatogenesis.

What makes kisspeptin particularly relevant in clinical research is that it activates the reproductive axis in a physiological and pulsatile manner — unlike long-acting GnRH analogs (continuous agonists like leuprolide), which paradoxically suppress the axis through receptor desensitization.

KNDy Neurons and the Pulse Generator

Arcuate nucleus neurons co-express kisspeptin along with two additional neuropeptides: neurokinin B (NKB) and dynorphin. This assembly is known as “KNDy neurons” (Kisspeptin-Neurokinin B-Dynorphin) and functions as the pulse generator for the reproductive axis. NKB auto-stimulates pulsatile kisspeptin secretion, while dynorphin acts as a feedback brake. This system is sensitive to estrogens, leptin, chronic cortisol, and energy deficit, explaining how stress and severe caloric restriction suppress reproductive function through the kisspeptin pathway.

Research Applications

Functional Hypothalamic Amenorrhea (FHA)

FHA is the most common cause of secondary amenorrhea in women of reproductive age, precipitated by energy deficit, excessive exercise, or chronic stress. All of these factors inhibit KNDy neurons, silencing the GnRH-LH-FSH axis. Exogenous kisspeptin can “awaken” these neurons and restore GnRH pulsatility without the side effects of continuous GnRH agonists.

Studies in women with FHA show that kisspeptin infusion restores LH pulses and, in prolonged protocols, has induced ovulatory cycles.

Ovulatory Trigger in In Vitro Fertilization (IVF)

In IVF protocols, the ovulatory trigger (final oocyte maturation trigger) is conventionally administered with HCG. However, HCG has a prolonged half-life (24-36h) and can produce ovarian hyperstimulation syndrome (OHSS), a potentially serious complication in women with high ovarian response.

Kisspeptin-54 has been shown in clinical trials (including the one published in NEJM in 2014 by Jayasena et al.) to induce a more physiological and shorter-duration endogenous LH surge, significantly reducing the risk of OHSS while maintaining comparable oocyte maturation and pregnancy rates.

Male Fertility

In hypogonadotropic hypogonadism, kisspeptin can stimulate pulsatile LH and FSH secretion, which in turn activates spermatogenesis and endogenous testosterone production.

Research Protocol

Morning injection is preferred to align with the endogenous pulsatile rhythm of GnRH, which is most active in the early hours of the day. In women, the protocol may be adjusted according to the phase of the menstrual cycle.

Note on tachyphylaxis: Very prolonged continuous use at high doses may produce GPR54 desensitization, reducing the response. 12-week cycles with rest periods are the most commonly reported approach in the research literature.

Storage

• Unreconstituted lyophilized powder: -20°C. Tolerates freezing and can be stored for up to 12 months without significant loss of activity.
• After reconstitution: 2-8°C for up to 4 weeks. Do not freeze the reconstituted solution. Protect from light.

Documented Adverse Effects

Kisspeptin is generally considered well tolerated in published clinical trials:

• Headache: Reported in some participants, generally mild and transient.
• Nausea: Less common than with direct exogenous GnRH.
• Ovarian hyperstimulation: In women on IVF protocols with high ovarian reserve, although the risk is considerably lower than with HCG.
• No significant cardiovascular effects: Clinical trials have not reported relevant changes in blood pressure or heart rate at physiological doses.

Regulatory Framework

Kisspeptin has no approved indications from the FDA or EMA for general therapeutic use. Active research is underway in multiple registered clinical trials for FHA, IVF, differential diagnosis of hypogonadism, and potentially for the treatment of libido disorders. Research vials are an unregulated product not classified as a pharmaceutical drug.

This content is for educational purposes only. Not medical advice. Always consult a healthcare professional before starting any research protocol.

Reported protocol (research reference)